This follow-up report is submitted to fda in accord with applicable regulations ¿ and as indicated by terumo cardiovascular systems in the initial report submitted to the fda on apr 10, 2019.Upon further investigation of the reported event, the following information is new and/or changed: d10 (device availability ¿ added date returned to manufacturer).G4 (date received by manufacturer).G7 (indication that this is a follow-up report).H2 (follow-up due to additional information).H3 (device evaluation anticipated by manufacturer ¿ a second follow-up will be submitted upon completion of the investigation and/or submission of new information, thus tcvs references conclusions code 11.) all available information has been placed on file in quality management for appropriate tracking, trending, and follow-up.
|
This follow-up report is submitted to fda in accord with applicable regulations.Upon further investigation of the reported event, the following information is new and/or changed: d4 (additional device information - added exp date).G4 (date received by manufacturer).G7 (indication that this is a follow-up report).H2 (follow-up due to additional information and device evaluation).H3 (device evaluated by manufacturer).H4 (device manufacture date).H6 (identification of evaluation codes 10, 11, 3331, 213, 67).Method code #1: 10 - actual device evaluated.Method code #2: 11 - testing of device from same lot/batch retained by manufacturer.Method code #3: 3331 - analysis of production records.Results code: 213 - no device problem found.Conclusions code: 67 - no problem detected.The returned cap was visually inspected and no anomalies were noted.Additionally, a representative retention sample from the same lot number combination was obtained.There were no visual anomalies noted with the retention caps.Ftir analysis was conducted on the received sample, the retention sample, and an additional sample from production.The ftir analysis was completed by an independent laboratory.Each of the samples came back with no presence of foreign contamination.The analysis indicated polypropylene, which is the composition of the cap.The investigation verified that the sample did not contain any foreign contaminates.A root cause for the allergic reaction could not be determined as there were no foreign contaminates present.All available information has been placed on file in quality management for appropriate tracking, trending, and follow-up.
|